Background
Background The National Institute
The National Institute for Clinical Excellence in the UKhas for Clinical Excellence in the UK has recommended limiting the use of recommended limiting the use of electroconvulsive therapy (ECT), partly electroconvulsive therapy (ECT), partly because of the inadequacy of research into because of the inadequacy of research into the effects of ECTon quality of life and the effects of ECTon quality of life and function. function.
Aims Aims To examine the effects of ECT
To examine the effects of ECT on function and quality of life, particularly on function and quality of life, particularly as they relate to changes in mood and as they relate to changes in mood and cognition in the month following this cognition in the month following this therapy. therapy.
Method Method We measured changes in
We measured changes in quality of life, function, mood and quality of life, function, mood and cognition in a prospective sample of 77 cognition in a prospective sample of 77 depressed patients given ECT. depressed patients given ECT.
Results

Results All quality of life and function
All quality of life and function outcomes were improved atthe 2-week outcomes were improved atthe 2-week and 4-week marks after ECT. and 4-week marks after ECT. Improvement in quality of life was related Improvement in quality of life was related to mood, whereas improvement in to mood, whereas improvement in instrumental activities of daily living instrumental activities of daily living function was related to improvement in function was related to improvement in global cognition. global cognition.
Conclusions Conclusions Electroconvulsive
Electroconvulsive therapy is associated with early therapy is associated with early improvementin function and quality of life. improvementin function and qualityof life. A restrictive attitude towards this therapy A restrictive attitude towards this therapy is not warranted on the basis of its effects is not warranted on the basis of its effects on quality of life and function. on quality of life and function.
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Electroconvulsive therapy (ECT) is widely Electroconvulsive therapy (ECT) is widely acknowledged as an effective and approacknowledged as an effective and appropriate acute treatment for major depressive priate acute treatment for major depressive illness (American Psychiatric Association illness (American Psychiatric Association Committee on Electroconvulsive Therapy, Committee on Electroconvulsive Therapy, 2001; UK ECT Review Group, 2003) . 2001; UK ECT Review Group, 2003) . However, questions remain regarding the However, questions remain regarding the extent and longevity of the effects of this extent and longevity of the effects of this therapy on memory, and whether ECT is therapy on memory, and whether ECT is associated with a net improvement in associated with a net improvement in function and quality of life. Correspondfunction and quality of life. Correspondingly, guidance on the use of ECT in the ingly, guidance on the use of ECT in the UK issued by the National Institute for UK issued by the National Institute for Clinical Excellence (NICE) recommended Clinical Excellence (NICE) recommended sharp restrictions on the use of this therapy sharp restrictions on the use of this therapy until more information becomes available until more information becomes available about its effects on memory, quality of life about its effects on memory, quality of life and other pertinent health outcomes and other pertinent health outcomes (National Institute for Clinical Excellence, (National Institute for Clinical Excellence, 2003) . The NICE guidance states that 'no 2003) . The NICE guidance states that 'no study adequately captured . . . quality of study adequately captured . . . quality of life' and that 'better quality-of-life inforlife' and that 'better quality-of-life information is needed for people considered mation is needed for people considered for, or who have received, ECT' (National for, or who have received, ECT' (National Institute for Clinical Excellence, 2003: Institute for Clinical Excellence, 2003: paras 4.1.2, 5.5). paras 4.1.2, 5.5).
Indeed, the literature on mood and cogIndeed, the literature on mood and cognition has generally shown that poorer nition has generally shown that poorer cognitive status is associated with worse cognitive status is associated with worse quality of life in patients with depression. quality of life in patients with depression. These relationships are true whether the These relationships are true whether the sample of interest is patients with depressample of interest is patients with depression secondary to dementia (Pearson sion secondary to dementia (Pearson et al et al, , 1989) or patients with primary depression 1989) or patients with primary depression and secondary cognitive dysfunction and secondary cognitive dysfunction (McCall & Dunn, 2003) . These observa- (McCall & Dunn, 2003) . These observations suggest that the cognitive side-effects tions suggest that the cognitive side-effects of ECT should limit any beneficial antiof ECT should limit any beneficial antidepressant effect on quality of life. Howdepressant effect on quality of life. However, we and others have previously ever, we and others have previously shown that ECT results in a net improveshown that ECT results in a net improvement in function and quality of life for a ment in function and quality of life for a period of at least 1 year after treatment period of at least 1 year after treatment (McCall (McCall et al et al, 2001; Casey , 2001; Casey et al et al, 1996) . , 1996). We have therefore examined the simulWe have therefore examined the simultaneous, respective contributions of antidetaneous, respective contributions of antidepressant efficacy and cognitive side-effects pressant efficacy and cognitive side-effects to the changes in function and quality of to the changes in function and quality of life in patients given ECT. We began with life in patients given ECT. We began with the hypothesis that antidepressant efficacy the hypothesis that antidepressant efficacy would be associated with improvement in would be associated with improvement in function and quality of life, whereas cognifunction and quality of life, whereas cognitive side-effects would be associated with a tive side-effects would be associated with a dampening of function and quality of life in dampening of function and quality of life in patients treated with ECT. patients treated with ECT.
METHOD METHOD
Study sample Study sample
The sample was recruited from patients The sample was recruited from patients with major depressive episode diagnosed with major depressive episode diagnosed on the basis of a structured interview on the basis of a structured interview (Ventura (Ventura et al et al, 1998) . Written informed , 1998). Written informed consent was obtained after a complete consent was obtained after a complete description of the study had been given to description of the study had been given to the participants, and the protocol was the participants, and the protocol was approved by the local institutional review approved by the local institutional review board. Participants were at least 18 years board. Hamilton, 1960) were 20 or over. The adequacy of 1960) were 20 or over. The adequacy of antidepressant drug therapy during the antidepressant drug therapy during the current major depressive episode was detercurrent major depressive episode was determined using a dichotomised rating scale mined using a dichotomised rating scale (adequate treatment (adequate treatment v.
v. inadequate treatinadequate treatment) (Prudic ment) (Prudic et al et al, 1996; McCall , 1996; McCall et al et al, , 1999 McCall et al et al, , 1999a Sackeim, 2001) . Antidepressants, ; Sackeim, 2001). Antidepressants, anticonvulsants and lithium were disconanticonvulsants and lithium were discontinued prior to the first ECT session and tinued prior to the first ECT session and benzodiazepines were tapered to 4 mg or benzodiazepines were tapered to 4 mg or less per day of lorazepam or its equivalent. less per day of lorazepam or its equivalent. Participants received open treatment with Participants received open treatment with antidepressant medication during the antidepressant medication during the month-long period of observation after month-long period of observation after ECT, with the choice of medication deter-ECT, with the choice of medication determined by the attending physician. mined by the attending physician.
Procedure Procedure
Right unilateral electrode placement Right unilateral electrode placement followed the d'Elia position, whereas bilatfollowed the d'Elia position, whereas bilateral placement was in the frontotemporal eral placement was in the frontotemporal position (D'Elia & Raotma, 1975) . position (D'Elia & Raotma, 1975 , 1988) , and a trained rater masked to patient status meatrained rater masked to patient status measured depression severity with the 21-item sured depression severity with the 21-item HRSD following a semi-structured inter-HRSD following a semi-structured interview. The HRSD was completed 1-3 days view. The HRSD was completed 1-3 days prior to the first ECT session, 24 h after prior to the first ECT session, 24 h after each mid-course session, 1-2 days after each mid-course session, 1-2 days after the last session, and 2 weeks and 4 weeks the last session, and 2 weeks and 4 weeks after the last session. The BDI was comafter the last session. The BDI was completed before and immediately after the pleted before and immediately after the course of therapy, and at 2 weeks and 4 course of therapy, and at 2 weeks and 4 weeks after the last session. Antidepressant weeks after the last session. Antidepressant response was defined as a decrease of at response was defined as a decrease of at least 60% in HRSD scores and a final score least 60% in HRSD scores and a final score of 12 or less after completion of the of 12 or less after completion of the therapy. Relapse among the responders therapy. Relapse among the responders was defined as a 50% increase in HRSD was defined as a 50% increase in HRSD scores from the end of therapy and an scores from the end of therapy and an HRSD score of 14 or more at both the 2-HRSD score of 14 or more at both the 2-week and the 4-week intervals. week and the 4-week intervals.
Cognitive assessment Cognitive assessment
Cognition was assessed 1-3 days prior to Cognition was assessed 1-3 days prior to ECT, 1-2 days after the course of ECT ECT, 1-2 days after the course of ECT and at 2 and 4 weeks after ECT by a and at 2 and 4 weeks after ECT by a masked rater. Global cognition was evalumasked rater. Global cognition was evaluated with the MMSE. an activities of daily living scale, the an activities of daily living scale, the Personal Self-Maintenance Scale (PSMS; Personal Self-Maintenance Scale (PSMS; Lawton & Brody, 1969) . The IADL scale Lawton & Brody, 1969) . The IADL scale has been shown to be sensitive to change has been shown to be sensitive to change in this sample and to demonstrate good rein this sample and to demonstrate good reliability between patients and their careliability between patients and their caregivers, with a correlation of 0.95 for the givers, with a correlation of 0.95 for the change scores (McCall change scores (McCall et al et al, 2002 (McCall et al et al, , 2002b . Qual-). Quality of life was assessed with the Daily Living ity of life was assessed with the Daily Living and Role Functioning (DLRF) sub-scale and Role Functioning (DLRF) sub-scale and the Relationship to Self and Others and the Relationship to Self and Others (RSO) sub-scale of the Basis-32 instrument (RSO) sub-scale of the Basis-32 instrument (Eisen (Eisen et al et al, 1994) . , 1994).
Statistics Statistics
Means are reported with standard deviaMeans are reported with standard deviations. The means of continuous variables tions. The means of continuous variables were compared with were compared with t t tests or adjusted tests or adjusted analyses of variance. Frequency distrianalyses of variance. Frequency distributions were compared with the butions were compared with the w w 2 2 statistic. statistic. Models of the change in function and Models of the change in function and quality of life were created for the 2-week quality of life were created for the 2-week and 4-week post-ECT time points, comand 4-week post-ECT time points, compared with the pre-ECT baseline. A total pared with the pre-ECT baseline. A total of eight linear regression models were of eight linear regression models were created (DLRF, RSO, IADL and PSMS created (DLRF, RSO, IADL and PSMS scores at both 2 weeks and 4 weeks). All scores at both 2 weeks and 4 weeks). All measurements within the models were measurements within the models were expressed as the percentage change from expressed as the percentage change from baseline, with the exception of age and baseline, with the exception of age and gender. Predictor variables were initially gender. Predictor variables were initially handled as block variables. Age and gender handled as block variables. Age and gender were grouped as the block variable 'demowere grouped as the block variable 'demographic', the BDI and HRSD scores were graphic', the BDI and HRSD scores were grouped as the block variable 'mood' and grouped as the block variable 'mood' and the MMSE, RAVLT-DR, RCFT-DR and the MMSE, RAVLT-DR, RCFT-DR and autobiographical memory measures were autobiographical memory measures were grouped as 'cognitive'. The models all fit grouped as 'cognitive'. The models all fit the general formula (Function/QOL) the general formula (Function/QOL)¼ ( (a a+ +b b 1 1 demographic+ demographic+b b 2 2 mood+ mood+b b 3 3 cognitive). cognitive). If the overall model was significant, we If the overall model was significant, we then examined which of the block variables then examined which of the block variables was significant. Finally, only if a block was significant. Finally, only if a block variable was significant did we examine variable was significant did we examine the component variables of the block to test the component variables of the block to test their significance within the full model and their significance within the full model and within univariate regressions. Statistical within univariate regressions. Statistical significance was accepted for significance was accepted for a a set at set at 0.05. All tests were two-sided. 0.05. All tests were two-sided.
RESULTS RESULTS
Participants allocated to bilateral or right Participants allocated to bilateral or right unilateral electrode placement were similar, unilateral electrode placement were similar, and the groups were not significantly differand the groups were not significantly different in age, gender, educational attainment, ent in age, gender, educational attainment, adequacy of antidepressant medication adequacy of antidepressant medication therapy at all time points, pre-treatment therapy at all time points, pre-treatment severity of depressive symptoms, duration severity of depressive symptoms, duration of the current episode, number of prior of the current episode, number of prior depressive episodes and age at onset of the depressive episodes and age at onset of the first depressive episode. Similarly, there first depressive episode. Similarly, there was no statistically or clinically significant was no statistically or clinically significant between-group difference for antidepresbetween-group difference for antidepressant response or cognitive side-effects at sant response or cognitive side-effects at any time point (McCall any time point (McCall et al et al, 2002 , 2002a a; Table  ; Table  1 ). We therefore pooled the results from 1). We therefore pooled the results from both groups for all subsequent analysis. In both groups for all subsequent analysis. In general, prior to ECT, participants were general, prior to ECT, participants were severely depressed, had minimal cognitive severely depressed, had minimal cognitive dysfunction and had significant deficits dysfunction and had significant deficits in quality of life and functional status in quality of life and functional status (Table 2) . (Table 2) .
Sixty-two patients (81%) met our defiSixty-two patients (81%) met our definition of 'adequate treatment' prior to nition of 'adequate treatment' prior to ECT, and 39 (55%) and 47 (70%) met ECT, and 39 (55%) and 47 (70%) met the definition at 2 weeks and 4 weeks, the definition at 2 weeks and 4 weeks, respectively (Prudic respectively (Prudic et al et al, 1996 ). Prescribed , 1996 . Prescribed antidepressant regimens at 2 weeks included antidepressant regimens at 2 weeks included selective serotonin reuptake inhibitors (17 selective serotonin reuptake inhibitors (17 patients); venlafaxine (13 pa patients); venlafaxine (13 patients), atypical tients), atypical antidepressants (bupropion, mirtazapine or antidepressants (bupropion, mirtazapine or nefazodone; 22 patients), tricyclic antinefazodone; 22 patients), tricyclic antidepressants (12 patients, including depressants (12 patients, including 3 on 3 on lithium) and monoamine oxidase inhibitors lithium) and monoamine oxidase inhibitors (2 patients). The antidepressant regimens at (2 patients). The antidepressant regimens at 4 weeks were similar. 4 weeks were similar.
Forty-one participants from the full Forty-one participants from the full sample of 77 patients had complete data sample of 77 patients had complete data for every variable at every time point. Missfor every variable at every time point. Missing data from the other 36 patients were asing data from the other 36 patients were assumed to be missing at random; therefore sumed to be missing at random; therefore imputation techniques were not employed. imputation techniques were not employed. Pre-post difference scores and regression Pre-post difference scores and regression models were examined for both all availmodels were examined for both all available data (full data-set) and for the 41 able data (full data-set) and for the 41 participants with a complete data-set. participants with a complete data-set. Statistical inference was the same for both Statistical inference was the same for both 4 0 6 4 0 6 the full data-set and the complete data-set; the full data-set and the complete data-set; therefore, results are presented only for therefore, results are presented only for the full data-set. the full data-set. The immediate post-ECT responder The immediate post-ECT responder rate was 66%, with 37% of the responders rate was 66%, with 37% of the responders relapsing within the first month after ECT. relapsing within the first month after ECT. The sample showed improvement in every The sample showed improvement in every measure of mood, cognition, quality of measure of mood, cognition, quality of life and function at both the 2-week and life and function at both the 2-week and 4-week time points, except for the auto-4-week time points, except for the autobiographical memory test (which is only biographical memory test (which is only designed to reveal memory loss, not designed to reveal memory loss, not improvement). Further, the change in the improvement). Further, the change in the nine variables showing improvement was nine variables showing improvement was statistically significant, except for the statistically significant, except for the RAVLT-DR (Table 2) . RAVLT-DR (Table 2) .
Although most patients experienced Although most patients experienced improved quality of life and function at improved quality of life and function at the 2-week and 4-week assessments, a few the 2-week and 4-week assessments, a few had worse scores. There were 70 patients had worse scores. There were 70 patients who had complete scores for baseline and who had complete scores for baseline and 2-week measures of DLRF, RSO, IADL 2-week measures of DLRF, RSO, IADL and PSMS, including 3, 8, 14 and 12 paand PSMS, including 3, 8, 14 and 12 patients who had worse scores on the respectients who had worse scores on the respective scales. There were 67 patients who had tive scales. There were 67 patients who had complete scores for baseline and 4-week complete scores for baseline and 4-week measures of DLRF, RSO, IADL and PSMS, measures of DLRF, RSO, IADL and PSMS, including 3, 8, 6 and 8 who had worse including 3, 8, 6 and 8 who had worse scores, respectively. Compared with pascores, respectively. Compared with patients with improved quality of life and tients with improved quality of life and function, patients with worse quality of life function, patients with worse quality of life or function scores had lower baseline or function scores had lower baseline HRSD and RCFT-DR scores, greater HRSD and RCFT-DR scores, greater decrements decrements in retrograde memory and less in retrograde memory and less improvement in HRSD score. improvement in HRSD score.
All of the models of the change in All of the models of the change in DLRF and RSO scores were highly signifi-DLRF and RSO scores were highly significant, and mood was the only significant cant, and mood was the only significant block variable (Table 3) . Fractionation of block variable (Table 3) . Fractionation of the 'mood' block revealed that only the the 'mood' block revealed that only the HRSD was statistically related to DLRF HRSD was statistically related to DLRF or RSO when the HRSD and BDI measures or RSO when the HRSD and BDI measures were both present in the models. Reducwere both present in the models. Reductions in depression severity were associated tions in depression severity were associated with reductions in deficits in DLRF and with reductions in deficits in DLRF and RSO. RSO.
The significant model of function was The significant model of function was IADL at 2 weeks after ECT. 'Cognitive' IADL at 2 weeks after ECT. 'Cognitive' was the only block variable that was signifwas the only block variable that was significant within that model. Further fractionaicant within that model. Further fractionation of 'cognitive' showed that only the tion of 'cognitive' showed that only the change in the MMSE score was related to change in the MMSE score was related to the change in IADL score at 2 weeks the change in IADL score at 2 weeks ( (r r¼0.3, 0.3, P P5 50.05; 0.05; n n¼67). The contribution 67). The contribution of the MMSE to the variance of IADL score of the MMSE to the variance of IADL score could not be explained away as a confound could not be explained away as a confound of mood, as the change in MMSE score and of mood, as the change in MMSE score and the change in the HRSD score at 2 weeks the change in the HRSD score at 2 weeks were not related ( were not related (r r¼7 70.1, 0.1, P P¼0.38; 0.38; n n¼69). 69).
DISCUSSION DISCUSSION
A key finding of this study is that patients' A key finding of this study is that patients' quality of life and function are improved as quality of life and function are improved as early as 2 weeks after the completion of early as 2 weeks after the completion of ECT. We have previously reported that ECT. We have previously reported that function and quality of life improve after function and quality of life improve after ECT, and to a greater extent than in ECT, and to a greater extent than in medication-treated patients, but in that medication-treated patients, but in that study the first measurement was taken at study the first measurement was taken at 4 weeks after ECT (McCall 4 weeks after ECT (McCall et al et al, 2001) . , 2001). The relevance of our findings is underThe relevance of our findings is underscored by our prior report that function scored by our prior report that function and quality of life measures appear to be and quality of life measures appear to be key indicators for the use of ECT in key indicators for the use of ECT in depressed patients (McCall depressed patients (McCall et al et al, 1999 (McCall et al et al, , 1999b , ), and that improvement in these domains is and that improvement in these domains is 4 0 7 4 0 7 Table 3  Table 3 Determinants of quality of life and function Determinants of quality of life and function sustained for up to 1 year in patients treated sustained for up to 1 year in patients treated with ECT (Casey with ECT (Casey et al et al, 1996; McCall , 1996; McCall et al et al, , 2001 McCall et al et al, , 2001 . ).
The change in our quality of life The change in our quality of life measures (DLRF and RSO) was related to measures (DLRF and RSO) was related to change in mood. This is consistent with change in mood. This is consistent with earlier cross-sectional and longitudinal data earlier cross-sectional and longitudinal data which showed that mood, not cognition, which showed that mood, not cognition, was related to these two variables (McCall was related to these two variables (McCall et al et al, 1999 (McCall et al et al, , 1999a (McCall et al et al, a, 2001 McCall & Dunn, 2003) . , 2001; McCall & Dunn, 2003) . The finding that only the change in HRSD The finding that only the change in HRSD score, not the change in BDI score, was score, not the change in BDI score, was significantly related to change in quality significantly related to change in quality of life when both the HRSD and BDI were of life when both the HRSD and BDI were in the models may be explained by the use in the models may be explained by the use of the HRSD to determine response status of the HRSD to determine response status to ECT. The decision to continue or stop to ECT. The decision to continue or stop ECT was in part related to change in the ECT was in part related to change in the HRSD score, not the BDI score. HRSD score, not the BDI score.
Although our sample showed improveAlthough our sample showed improvement in both measures of function at the ment in both measures of function at the 2-week and 4-week time points (Table 2) , 2-week and 4-week time points (Table 2) , our models could only predict the change our models could only predict the change in IADL at 2 weeks. Interestingly, change in IADL at 2 weeks. Interestingly, change in IADL at 2 weeks was most closely in IADL at 2 weeks was most closely related to change in cognition, not mood. related to change in cognition, not mood. In particular, improvement in the MMSE, In particular, improvement in the MMSE, but not any of the specific memory but not any of the specific memory measures, was related to improvement in measures, was related to improvement in IADL at 2 weeks. This is consistent with IADL at 2 weeks. This is consistent with our earlier finding that baseline IADL funcour earlier finding that baseline IADL function in patients treated with ECT is related tion in patients treated with ECT is related to the MMSE score but not to mood to the MMSE score but not to mood (McCall & Dunn, 2003) . (McCall & Dunn, 2003) .
Given the extensive research on cogniGiven the extensive research on cognitive deficits related to ECT, it may seem tive deficits related to ECT, it may seem remarkable that our measures of global remarkable that our measures of global cognition, anterograde verbal memory and cognition, anterograde verbal memory and anterograde figural memory showed anterograde figural memory showed improvement at 2 weeks and 4 weeks after improvement at 2 weeks and 4 weeks after ECT compared with the pre-therapy base-ECT compared with the pre-therapy baseline. However, cognitive improvement with line. However, cognitive improvement with ECT has been reported repeatedly over the ECT has been reported repeatedly over the past 40 years (Fink, 1979; Pisvejc past 40 years (Fink, 1979; Pisvejc et al et al, , 1998) . Cognitive problems may be an in-1998). Cognitive problems may be an intrinsic part of depressive illness (Weintrinsic part of depressive illness (Weingartner gartner et al et al, 1981; King , 1981; King et al et al, 1991), and , 1991) , and it is logical that treatment of depression it is logical that treatment of depression should be associated with improvement on should be associated with improvement on cognitive tests. Although the improvement cognitive tests. Although the improvement on neuropsychological tests could be attribon neuropsychological tests could be attributed to a practice effect, it is equally likely uted to a practice effect, it is equally likely that it represents true improvement in cogthat it represents true improvement in cognitive efficiency in patients whose cognitive nitive efficiency in patients whose cognitive efficiency had been overtaxed by depresefficiency had been overtaxed by depression. Similar findings of improved cognision. Similar findings of improved cognition have been reported in stroke patients tion have been reported in stroke patients recovering from depression (Narushima recovering from depression (Narushima et et al al, 2003) and in clinical trials of antidepres-, 2003) and in clinical trials of antidepressant medication in primary depression sant medication in primary depression (Reynolds (Reynolds et al et al, 1987; Reifler , 1987; Reifler et al et al, 1989; , 1989; Newhouse Newhouse et al et al, 2000; Cassano , 2000; Cassano et al et al, , 2002 Cassano et al et al, , ). 2002 .
This study has some limitations. The This study has some limitations. The number of participants was small, and there number of participants was small, and there were some missing data. Still, the results were some missing data. Still, the results from the 'all available' (full) data-set led from the 'all available' (full) data-set led to the same inference as did the results of to the same inference as did the results of the complete data-set. Patients received natthe complete data-set. Patients received naturalistic treatment during follow-up with a uralistic treatment during follow-up with a wide range of antidepressant medications in wide range of antidepressant medications in various dosages as prophylaxis against revarious dosages as prophylaxis against relapse. It is unclear how medication status lapse. It is unclear how medication status might have affected mood, cognition, qualmight have affected mood, cognition, quality of life and function. Although the folity of life and function. Although the follow-up period was only a month long, the low-up period was only a month long, the mood, cognitive and neurophysiological efmood, cognitive and neurophysiological effects of ECT fade within weeks, perhaps fects of ECT fade within weeks, perhaps with the exception of persistent autobiograwith the exception of persistent autobiographical memory loss. Although autobiographical memory loss. Although autobiographical memory did not figure into any of phical memory did not figure into any of our models during the first month of folour models during the first month of follow-up, it might be more important to low-up, it might be more important to assessment of quality of life months after assessment of quality of life months after ECT. ECT.
In summary, ECT is associated with imIn summary, ECT is associated with improvement in quality of life, function, provement in quality of life, function, mood, anterograde memory and global mood, anterograde memory and global cognitive status at 2 weeks and 4 weeks cognitive status at 2 weeks and 4 weeks after this therapy. Most patients experiafter this therapy. Most patients experienced improvement in quality of life and enced improvement in quality of life and function. Change in perceived quality of life function. Change in perceived quality of life seems to be most influenced by changes in seems to be most influenced by changes in mood, whereas change in IADL function mood, whereas change in IADL function at 2 weeks was related to change in global at 2 weeks was related to change in global cognition. The results are consistent with cognition. The results are consistent with the premise that ECT produces a net the premise that ECT produces a net improvement in health for most patients, improvement in health for most patients, and should help fill in the knowledge gap and should help fill in the knowledge gap that led to the restrictive guidance on the that led to the restrictive guidance on the use of ECT in the UK (National Institute use of ECT in the UK (National Institute for Clinical Excellence, 2003) . for Clinical Excellence, 2003) .
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